laitimes

After the flash crash of "Northeast Yaomao", it fell to a halt, and the stock price shrank by 60% in eight months! What's going on?

author:Sino-Singapore warp and weft

Zhongxin Jingwei January 20, following the flash crash on January 19, on the 20th, Changchun High-tech, known as "Northeast Yaomao", fell to a stop at the opening of 204.84 yuan / share, and the market value fell to 82.9 billion yuan.

  On January 19, after more than a month of continuous declines, Changchun High-tech suddenly crashed and stopped. In the long run, Changchun Gaoxin's stock price hit an all-time high of 552.17 yuan / share (before the restoration) on May 17, 2021 and then turned downwards, calculated at 204.84 yuan / share, a cumulative decline of 62.90% from the highest price.

  Public reports show that in May 2021, the market reported news of growth hormone collection. On January 19 this year, the Guangdong Provincial Drug Trading Center issued the Notice of Drug Collection of Guangdong Alliance, and among the 276 drug procurement lists, the recombinant human growth hormone of Kinsey Pharmaceutical, Anke Biotech and other companies was included in the collection, and Kinsey Pharmaceutical was a subsidiary of Changchun High-tech.

After the flash crash of "Northeast Yaomao", it fell to a halt, and the stock price shrank by 60% in eight months! What's going on?

  Screenshot of the Interactive Easy website

  For the impact of the incident, Changchun High-tech responded on the interactive platform after hours on the same day: the company is currently actively studying the policy provisions and will formulate a reasonable plan, and there is no specific impact expected at present.

  According to Wind information, Changchun Gaoxin was established in June 1993 and is one of the earliest listed companies in northeast China. The company's main business is the production and sales of biopharmaceuticals and proprietary Chinese medicines, supplemented by real estate development and property management. Over the years of listing, the company condensed and adhered to the "innovation, focus, inclusive, sharing" development concept, adhere to scientific and technological innovation as the source of power, the leading industry successfully realized the transformation from serving the infrastructure construction of the development zone to the biopharmaceutical and health industry, with the successful incubation and growth of pharmaceutical industry projects, supporting the rapid growth of business performance, the company has become a listed company with certain technological leading advantages in the domestic biomedical field. (Zhongxin Jingwei APP)

Read on